Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.

Bibliographic Details
Main Authors:	Yue Hao, Xinchao Yu, Yonghong Bai, Helen J McBride, Xin Huang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0217716

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Pertuzumab and trastuzumab: the rationale way to synergy
by: SANDRINE RICHARD, et al.
Published: (2016-01-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
by: Wei-Li Ling, et al.
Published: (2018-03-01)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
by: Elisabeth Sophie Bergen, et al.
Published: (2021-04-01)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
by: Juliana Bentes Hughes, et al.
Published: (2012-06-01)

Pertuzumab som tillägg till behandling med trastuzumab och docetaxel vid metastaserad HER2-positiv bröstcancer
by: Bunmeepom, Wiphawee
Published: (2015)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
by: Sara Lonardi, et al.
Published: (2020-10-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
by: Edith A. Perez, et al.
Published: (2019-06-01)

Efficacy of trastuzumab-emtansine in breast cancer patients prior treated with pertuzumab
by: Sundfors, Anu-Johanna
Published: (2019)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
by: Ashley M. Hopkins, et al.
Published: (2019-08-01)

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
by: Joseph J. Maly, et al.
Published: (2014-05-01)

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
by: Joseph J. Maly, et al.
Published: (2014-01-01)

HER2‐positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab‐based chemotherapy: A case report
by: Raffaele Longo, et al.
Published: (2020-12-01)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
by: Jung Won Shin, et al.
Published: (2019-10-01)

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
by: Nadia Hussain, et al.
Published: (2018-01-01)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021-08-01)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
by: Edith A. Perez, et al.
Published: (2019-05-01)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
by: Toshinari Yamashita, et al.
Published: (2020-06-01)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
by: Tejal A. Patel, et al.
Published: (2019-09-01)

Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
by: Barrios, C., et al.
Published: (2022)

Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
by: Andrea Fontana
Published: (2018-06-01)

Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report
by: Valentina Magri, et al.
Published: (2018-10-01)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
by: Mayuko Ito, et al.
Published: (2021-02-01)

Role of pertuzumab in the treatment of HER2-positive breast cancer
by: Hubalek M, et al.
Published: (2012-05-01)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
by: Toshinari Yamashita, et al.
Published: (2020-05-01)

Totality of evidence for ABP 980, a trastuzumab biosimilar: results of chemo-synergy studies in combination with pertuzumab
by: H.-C. Kolberg, et al.
Published: (2021-04-01)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
by: Tamara Díaz-Redondo, et al.
Published: (2019-11-01)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
by: Moya-Horno I, et al.
Published: (2015-05-01)

Cardiotoxicity of Pertuzumab Containing Regimens for HER-2 Positive Breast Cancer
by: Lin, Michelle, et al.
Published: (2017)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Pharmacoeconomic analysis of pertuzumab in treatment of HER2-positive breast cancer in Ukraine
by: О. В. Мужичук, et al.
Published: (2021-03-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab
by: Zhang Y, et al.
Published: (2019-12-01)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
by: Jie Li, et al.
Published: (2020-09-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.

Similar Items

Similar Items